Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of AP214 for prevention of kidney injury after cardiac surgery
2010-022630-92Phase 2Completed
- Sponsor
- Action Pharma A/S
- Start
- Sep 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of modimelanotide in kidney failure and acute kidney failure (AKF) (3 arms), sponsored by Action Pharma A/S. Primary endpoints: Safety of AP214, Change in glomerular filtration rate (GFR) and 2 more. Started Sep 2010; status: completed.
02
Drugs
modimelanotide
03
Conditions
kidney failureacute kidney failure (AKF)
Beyond the preview
Go deeper on 2010-022630-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022630-92.